Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer

Tokujiro Yano, Tatsuro Okamoto, Seiichi Fukuyama, Yoshihiko Maehara

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Postoperative recurrence occurs in approximately half of patients with non-small cell lung cancer (NSCLC), even after complete resection. Disease recurrence after surgical resection reduces the patient's life expectancy sharply. The prognosis after postoperative recurrence is considered to largely depend on both the mode of first recurrence (distant, locoregional or combined) and the treatment modality: (1) The majority of cases of postoperative recurrence involve distant metastasis with or without locoregional recurrence. Platinum-based systemic chemotherapy is practically accepted as the treatment for these diseases on the basis of evidence for original stage ? disease. The advent of both pemetrexed and molecular-targeted drugs has improved the survival of nonsquamous NSCLC and changed the chemotherapeutic algorithm for NSCLC; (2) Among patients with distant metastatic recurrence without locoregional recurrence at the primary tumor site, the metastasis is often limited in both organ and number. Such metastases are referred to as oligometastases. Local therapy, such as surgical resection and radiotherapy, has been suggested to be the first-line treatment of choice for oligometastatic recurrence; and (3) While locoregional recurrence is likely to cause troublesome symptoms, it is a potentially limited disease. Therefore, providing local control is important, and radiation is usually beneficial for treating local recurrence. In order to obtain better control of the disease and provide treatment with curative intent in patients with limited disease, the administration of concurrent platinum-based chemoradiotherapy is recommended according to the results of originally nonresectable stage ?A and ?B disease.

Original languageEnglish
Pages (from-to)1048-1054
Number of pages7
JournalWorld Journal of Clinical Oncology
Volume5
Issue number5
DOIs
Publication statusPublished - Dec 10 2014

Fingerprint

Non-Small Cell Lung Carcinoma
Recurrence
Therapeutics
Neoplasm Metastasis
Platinum
Pemetrexed
Chemoradiotherapy
Life Expectancy
Radiotherapy
Radiation
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. / Yano, Tokujiro; Okamoto, Tatsuro; Fukuyama, Seiichi; Maehara, Yoshihiko.

In: World Journal of Clinical Oncology, Vol. 5, No. 5, 10.12.2014, p. 1048-1054.

Research output: Contribution to journalReview article

Yano, Tokujiro ; Okamoto, Tatsuro ; Fukuyama, Seiichi ; Maehara, Yoshihiko. / Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. In: World Journal of Clinical Oncology. 2014 ; Vol. 5, No. 5. pp. 1048-1054.
@article{c4e0b377682d45baa148ac18bf20690d,
title = "Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer",
abstract = "Postoperative recurrence occurs in approximately half of patients with non-small cell lung cancer (NSCLC), even after complete resection. Disease recurrence after surgical resection reduces the patient's life expectancy sharply. The prognosis after postoperative recurrence is considered to largely depend on both the mode of first recurrence (distant, locoregional or combined) and the treatment modality: (1) The majority of cases of postoperative recurrence involve distant metastasis with or without locoregional recurrence. Platinum-based systemic chemotherapy is practically accepted as the treatment for these diseases on the basis of evidence for original stage ? disease. The advent of both pemetrexed and molecular-targeted drugs has improved the survival of nonsquamous NSCLC and changed the chemotherapeutic algorithm for NSCLC; (2) Among patients with distant metastatic recurrence without locoregional recurrence at the primary tumor site, the metastasis is often limited in both organ and number. Such metastases are referred to as oligometastases. Local therapy, such as surgical resection and radiotherapy, has been suggested to be the first-line treatment of choice for oligometastatic recurrence; and (3) While locoregional recurrence is likely to cause troublesome symptoms, it is a potentially limited disease. Therefore, providing local control is important, and radiation is usually beneficial for treating local recurrence. In order to obtain better control of the disease and provide treatment with curative intent in patients with limited disease, the administration of concurrent platinum-based chemoradiotherapy is recommended according to the results of originally nonresectable stage ?A and ?B disease.",
author = "Tokujiro Yano and Tatsuro Okamoto and Seiichi Fukuyama and Yoshihiko Maehara",
year = "2014",
month = "12",
day = "10",
doi = "10.5306/wjco.v5.i5.1048",
language = "English",
volume = "5",
pages = "1048--1054",
journal = "World Journal of Clinical Oncology",
issn = "2218-4333",
publisher = "Baishideng Publishing Group",
number = "5",

}

TY - JOUR

T1 - Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer

AU - Yano, Tokujiro

AU - Okamoto, Tatsuro

AU - Fukuyama, Seiichi

AU - Maehara, Yoshihiko

PY - 2014/12/10

Y1 - 2014/12/10

N2 - Postoperative recurrence occurs in approximately half of patients with non-small cell lung cancer (NSCLC), even after complete resection. Disease recurrence after surgical resection reduces the patient's life expectancy sharply. The prognosis after postoperative recurrence is considered to largely depend on both the mode of first recurrence (distant, locoregional or combined) and the treatment modality: (1) The majority of cases of postoperative recurrence involve distant metastasis with or without locoregional recurrence. Platinum-based systemic chemotherapy is practically accepted as the treatment for these diseases on the basis of evidence for original stage ? disease. The advent of both pemetrexed and molecular-targeted drugs has improved the survival of nonsquamous NSCLC and changed the chemotherapeutic algorithm for NSCLC; (2) Among patients with distant metastatic recurrence without locoregional recurrence at the primary tumor site, the metastasis is often limited in both organ and number. Such metastases are referred to as oligometastases. Local therapy, such as surgical resection and radiotherapy, has been suggested to be the first-line treatment of choice for oligometastatic recurrence; and (3) While locoregional recurrence is likely to cause troublesome symptoms, it is a potentially limited disease. Therefore, providing local control is important, and radiation is usually beneficial for treating local recurrence. In order to obtain better control of the disease and provide treatment with curative intent in patients with limited disease, the administration of concurrent platinum-based chemoradiotherapy is recommended according to the results of originally nonresectable stage ?A and ?B disease.

AB - Postoperative recurrence occurs in approximately half of patients with non-small cell lung cancer (NSCLC), even after complete resection. Disease recurrence after surgical resection reduces the patient's life expectancy sharply. The prognosis after postoperative recurrence is considered to largely depend on both the mode of first recurrence (distant, locoregional or combined) and the treatment modality: (1) The majority of cases of postoperative recurrence involve distant metastasis with or without locoregional recurrence. Platinum-based systemic chemotherapy is practically accepted as the treatment for these diseases on the basis of evidence for original stage ? disease. The advent of both pemetrexed and molecular-targeted drugs has improved the survival of nonsquamous NSCLC and changed the chemotherapeutic algorithm for NSCLC; (2) Among patients with distant metastatic recurrence without locoregional recurrence at the primary tumor site, the metastasis is often limited in both organ and number. Such metastases are referred to as oligometastases. Local therapy, such as surgical resection and radiotherapy, has been suggested to be the first-line treatment of choice for oligometastatic recurrence; and (3) While locoregional recurrence is likely to cause troublesome symptoms, it is a potentially limited disease. Therefore, providing local control is important, and radiation is usually beneficial for treating local recurrence. In order to obtain better control of the disease and provide treatment with curative intent in patients with limited disease, the administration of concurrent platinum-based chemoradiotherapy is recommended according to the results of originally nonresectable stage ?A and ?B disease.

UR - http://www.scopus.com/inward/record.url?scp=84928646475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928646475&partnerID=8YFLogxK

U2 - 10.5306/wjco.v5.i5.1048

DO - 10.5306/wjco.v5.i5.1048

M3 - Review article

AN - SCOPUS:84928646475

VL - 5

SP - 1048

EP - 1054

JO - World Journal of Clinical Oncology

JF - World Journal of Clinical Oncology

SN - 2218-4333

IS - 5

ER -